Medical cannabis research

PA Options for Wellness Opens First Medical Cannabis Dispensary in Harrisburg

Retrieved on: 
Monday, July 6, 2020
Medicine, Herbalism, Medicinal plants, Health sciences, Health, Cannabis industry, Medical cannabis research, Cannabis, Medical cannabis, Outline of cannabis, Steve DeAngelo

HARRISBURG, Pa., July 06, 2020 (GLOBE NEWSWIRE) -- PA Options for Wellness Inc. , a Pennsylvania-based medical cannabis research company, announced today the opening of its first dispensary, VYTAL Options , at 4711 Queen Avenue in Harrisburg.

Key Points: 
  • HARRISBURG, Pa., July 06, 2020 (GLOBE NEWSWIRE) -- PA Options for Wellness Inc. , a Pennsylvania-based medical cannabis research company, announced today the opening of its first dispensary, VYTAL Options , at 4711 Queen Avenue in Harrisburg.
  • PA Options for Wellness was founded in 2014 with a research and education-centered goal of becoming the leader in Pennsylvania's emerging medical cannabis industry.
  • PA Options for Wellness was founded by Thomas A. Trite, PD, FASCP, in 2014 with the goal of creating a premier medical cannabis service model and to be the leader in the emerging medical cannabis industry and cannabis research.
  • Headquartered in Harrisburg, PA Options for Wellness mission is to become the preferred provider of medical cannabis to qualified, approved patients through high quality products, and dignified, professional service.

Avicanna to Host Virtual Symposium Titled "Medical Cannabis 2.0" on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line

Retrieved on: 
Monday, June 22, 2020
Medicinal plants, Medicine, Entheogens, Euphoriants, Health, Cannabis smoking, Herbalism, Cannabis, Medical cannabis, Cannabinoid, Effects of cannabis, Medical cannabis research

Patients and health care practitioners globally can join the virtual symposium to learn more about the potential advantages of medical cannabis and the advancement of product offerings including Avicanna's RHO Phyto product offerings and advanced cannabinoid research collaboration at the University of Toronto.

Key Points: 
  • Patients and health care practitioners globally can join the virtual symposium to learn more about the potential advantages of medical cannabis and the advancement of product offerings including Avicanna's RHO Phyto product offerings and advanced cannabinoid research collaboration at the University of Toronto.
  • In addition, experts will discuss the pharmacology, safety, and dosing guidelinesofmedical cannabis for therapeutic conditions.
  • This includes presentations on the, efficacy of cannabinoids for chronic pain, anxiety, depression, and other comorbidities as well as an overview of the patient pathway to Medical Cannabis by Shoppers.
  • "In this unprecedent time, where patients and practitioners have many questions and are seeking alternative and natural solutions, we are pleased to welcome you all to our virtual symposium on medical cannabis.

Cannabis Science and Technology® Named 2020 SIPAwards Finalist

Retrieved on: 
Friday, June 12, 2020
Alternative medicine, Health, Other Health, Cannabis, Entheogens, Euphoriants, Medicinal plants, Rosids, Cannabis smoking, Legality of cannabis, Medical cannabis research, Outline of cannabis, Steep Hill Lab

Cannabis Science and Technology, a multimedia platform that focuses on educating the legal cannabis industry about the science and technology of analytical testing, quality control, extraction and cultivation, recently won third place in the Best Interview or Profile of Someone in Your Industry category during the 41st Annual SIPAwards virtual ceremony on June 2.

Key Points: 
  • Cannabis Science and Technology, a multimedia platform that focuses on educating the legal cannabis industry about the science and technology of analytical testing, quality control, extraction and cultivation, recently won third place in the Best Interview or Profile of Someone in Your Industry category during the 41st Annual SIPAwards virtual ceremony on June 2.
  • It is an incredible honor that Cannabis Science and Technology has been recognized as a finalist in the 2020 SIPAwards, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Cannabis Science and Technology.
  • The Cannabis Science and Technology entry titled Dr. Sue Sisley: Advocating for Medical Cannabis Research, Patients, and Reform highlights the pioneering research in the U.S. medical cannabis industry that Dr. Sue Sisley has been conducting, as well as her fight for quality cannabis samples to conduct her clinical trials.
  • Cannabis Science and Technology is a multimedia platform that focuses on educating the legal cannabis industry about the science and technology of analytical testing, quality control, extraction and cultivation.

Breastcancer.org Study Finds 4 in 10 Breast Cancer Patients Have Used Cannabis to Treat a Variety of Symptoms

Retrieved on: 
Thursday, May 14, 2020
Health, Medicine, RTT, Herbalism, Medicinal plants, Cannabis smoking, Cannabis, Medical cannabis, Breast cancer, Effects of cannabis, Cancer, Medical cannabis research

"We conducted this study, in part, to explore which symptoms breast cancer patients seek to control with cannabis and at what point during their treatment."

Key Points: 
  • "We conducted this study, in part, to explore which symptoms breast cancer patients seek to control with cannabis and at what point during their treatment."
  • Of the 612 completed surveys, 42% of respondents reported they have used medical cannabis to treat breast cancer symptoms or treatment side effects.
  • Key findings from the study:
    4 in 10 breast cancer patients say they have used cannabis to manage cancer-related symptoms.
  • Cannabis is used by breast cancer patients across a range of ages.

Health Canada Grants Cannabis Research License to the Joint R&D Project of Tree of Knowledge International Corp (TOKI) and Ryerson University

Retrieved on: 
Wednesday, March 18, 2020
Medicinal plants, Health, Medicine, Herbalism, Cannabis smoking, Entheogens, Euphoriants, Cannabis, Medical cannabis research, Medical cannabis, Effects of cannabis, Medical cannabis in the United States

Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience.

Key Points: 
  • Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience.
  • The Company has developed and implemented MCERP (Medical Cannabis Education, Research and Best Practice Platform) and MCORP (Medical Cannabis Opioid Reduction Program) with great success.
  • Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development.
  • TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

Retrieved on: 
Wednesday, February 19, 2020
Medicinal plants, Medicine, Health, Herbalism, Entheogens, Euphoriants, Cannabis smoking, Insomnia, Cannabis, Medical cannabis, Medical cannabis research, Cannabis use disorder

"This study represents the most rigorous clinical trial ever undertaken to assess the therapeutic potential of medicinal cannabis to treat the symptoms of chronic insomnia.

Key Points: 
  • "This study represents the most rigorous clinical trial ever undertaken to assess the therapeutic potential of medicinal cannabis to treat the symptoms of chronic insomnia.
  • It's also the first trial to use the Insomnia Severity Index, arguably the current gold standard in this field, to measure the efficacy of a medicinal cannabis product to treat insomnia symptoms.
  • Zelira is leading the development of clinically validated full spectrum cannabis medicines to access global markets for insomnia medications.
  • Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets.

Global Medical Marijuana Market Sees An Increase in Clinical Trials

Retrieved on: 
Friday, February 14, 2020
Cannabis, Drugs, Cannabinoids, Cannabis in the United Kingdom, GW Pharmaceuticals, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Nabiximols, Medical cannabis research

The "Medical Marijuana - Competitive Intelligence Analysis, 2019" report provides comprehensive insights into growth prospects in the Medical Marijuana industry.

Key Points: 
  • The "Medical Marijuana - Competitive Intelligence Analysis, 2019" report provides comprehensive insights into growth prospects in the Medical Marijuana industry.
  • GW Pharmaceuticals has two medical marijuana products in the market; Epidiolex and Sativex.
  • With the growing legalization of medical marijuana, more and more companies are investing in clinical trials with marijuana and its extracts to treat variety of indications.
  • The recent USFDA and European Commission Approval of Epidiolex, a plant-derived cannabidiol has contributed to overall growth of the medical marijuana industry.

Tilray, Inc. to Present at the 2020 ICR Conference

Retrieved on: 
Tuesday, January 7, 2020
Alternative medicine, Pharmaceutical, Health, Medicinal plants, Medicine, Health, Herbalism, Entheogens, Euphoriants, Tilray, Drug control law, Brendan Kennedy, Cannabis, Medical cannabis research, Legality of cannabis

Tilray, Inc., (Tilray or the Company) (Nasdaq: TLRY), a global leader in medical cannabis research, cultivation, production and distribution, today announced that Brendan Kennedy, President and Chief Executive Officer, will present at the 2020 ICR Conference.

Key Points: 
  • Tilray, Inc., (Tilray or the Company) (Nasdaq: TLRY), a global leader in medical cannabis research, cultivation, production and distribution, today announced that Brendan Kennedy, President and Chief Executive Officer, will present at the 2020 ICR Conference.
  • The presentation will be on Tuesday, January 14, 2020 at 11:00 a.m.
  • ET and the simultaneous, live webcast will be available on the Investors section of the Companys website at www.tilray.com .
  • Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 15 countries spanning five continents.

Tilray® Expands Global Presence with Successful Export to Switzerland

Retrieved on: 
Tuesday, December 17, 2019
Alternative medicine, Pharmaceutical, Health, Medicinal plants, Medicine, Health, Herbalism, Entheogens, Euphoriants, Tilray, Pharmaceuticals policy, Cannabis, Legality of cannabis, Medical cannabis research, Medical cannabis

Tilray, Inc. (Tilray or the Company) (NASDAQ: TLRY), a global leader in medical cannabis research, cultivation, production and distribution, today announced it has successfully exported medical cannabis extracts to Switzerland.

Key Points: 
  • Tilray, Inc. (Tilray or the Company) (NASDAQ: TLRY), a global leader in medical cannabis research, cultivation, production and distribution, today announced it has successfully exported medical cannabis extracts to Switzerland.
  • Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products.
  • The import and export permits were received in early December 2019, with the shipment of Tilrays medical cannabis extracts successfully arriving in Switzerland on December 13.
  • Following this first shipment of extracts, Tilray also anticipates exporting dried medical cannabis to Switzerland, offering patients an assortment of form factors to meet their varying medical indications.

INTERCURE: CANNDOC Initiates Phase 3 Clinical Trial Evaluating Pharma Grade Medicinal Cannabis (CANNDOC T1/C20) For Children With Autism Spectrum Disorder

Retrieved on: 
Thursday, November 21, 2019
Medicine, Health sciences, Health, Herbalism, Medicinal plants, Medical cannabis research, Cannabis, Medical cannabis

Enrolment in the study of approximately 100 patients age 8-18 is already underway, marking this study one of the most advanced pharma grade medicinal cannabis clinical trial.

Key Points: 
  • Enrolment in the study of approximately 100 patients age 8-18 is already underway, marking this study one of the most advanced pharma grade medicinal cannabis clinical trial.
  • Canndoc already supplies pharma grade cannabis products made to GMP standards, prescribe by physicians to patients in Israel and soon in other countries.
  • Alon Granot, CEO of Canndoc: "Our late stage clinical trial pipeline places Canndoc at the forefront of global clinical GMP-standard medical cannabis research.
  • Many families of children with autism spectrum disorder cope with significant difficulties in their lives.